BioCryst to present intravenous peramivir data for influenza treatment at IDSA meeting

Oct 21 2010

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) announced the presentation of data related to intravenous (i.v.) peramivir for the treatment of influenza at the 48^th Annual Infectious Diseases Society of America (IDSA) meeting being held in Vancouver, Canada.

“Clinical and Virologic Outcomes with Peramivir Therapy in Hospitalized Adults with Influenza B: Sub-Group Analysis of a Phase 2 Trial”

The data will be presented during a poster session scheduled for Friday, October 22, 2010 from 12:30-2:00 p.m. Eastern Time. The two posters to be presented during the session include:

• Presentation Number 761: "Clinical and Virologic Outcomes with Peramivir Therapy in Hospitalized Adults with Influenza B: Sub-Group Analysis of a Phase 2 Trial," which concludes that peramivir and oseltamivir treatment resulted in similar clinical outcomes in the overall study population>

• Presentation Number 765: "Neutropenia Is Not Related to Neuraminidase Inhibitor (NAI) Therapy of Uncomplicated Influenza in Phase 2 and 3 Controlled Clinical Trials," which describes the effects of influenza infection on lymphocyte and neutrophil populations and concludes that in placebo- or oseltamivir-controlled trials, peramivir has no apparent effects on leukocyte counts or risk of neutropenia in patients with influenza. Results were drawn from an analysis of data from five Phase 2 and Phase 3 clinical trials which included over 2,200 influenza patients treated with peramivir or a control.

Copies of the abstracts are available and can be viewed online through the IDSA Web site at www.idsociety.org/.